Company Strategy - The company focuses on unmet clinical needs, with a commitment to long-term growth and innovation in the cardiovascular-kidney-metabolic (CKM) disease area [4] - It aims to create social value and has established a strong brand in the chronic disease sector, particularly in hypertension and metabolic diseases [4] - The company has six patented drugs targeting hypertension and metabolic diseases, with plans to become the leading brand in hypertension medications in China [4][6] Recent Business Performance - In the first half of 2025, the company's revenue grew by 4.3% year-on-year, with a notable rebound of 12.3% in Q2 [6] - New product revenue now accounts for over 50% of total revenue, indicating successful market penetration [6] - The company maintains a low debt ratio and strong cash reserves, with R&D investment consistently above 20% of revenue [6] R&D Pipeline - The company has 74 new drugs in development, including 51 chemical drugs and 23 biological drugs, with over 50 projects focused on CKM diseases [7] - R&D efforts are supported by platforms in both China and the U.S., utilizing AI to enhance drug discovery and development efficiency [7][8] - The company is developing a comprehensive pipeline for hypertension treatments, aiming for a range of administration methods from daily to quarterly dosing [8] Innovative Drug Development - The company is advancing several first-in-class and best-in-class products for blood lipid management, including a monoclonal antibody for PCSK9 [11] - It is also exploring unique mechanisms for metabolic diseases, focusing on energy metabolism and muscle metabolism to address obesity and diabetes [11][19] - The company is committed to integrating innovation with healthcare policies to ensure rapid clinical application of research outcomes [8] Market Strategy - The company emphasizes academic promotion and patient education to enhance product penetration and disease awareness [14] - It is exploring digital chronic disease management models to improve patient lifecycle management and commercialize chronic disease treatments [14] - The company aims to leverage its products' entry into medical insurance to expand market coverage [14] Clinical Needs and Challenges - Cardiovascular diseases remain the leading cause of death globally, with significant unmet clinical needs in hypertension management [5] - The company recognizes the complexity of hypertension mechanisms and aims to provide tailored treatment solutions for various patient demographics [9][10] - The focus on differentiated strategies in a competitive market is crucial for establishing a unique position in the metabolic disease sector [19]

Group 1: Company Positioning and Strategy - The company positions itself as a differentiated player in the brokerage industry, focusing on "wealth management" and "investment banking" as strategic pillars, aiming to serve the real economy and residents' wealth management [2] - The company emphasizes a "non-directional transformation" and "equity-debt rebalancing," maintaining a focus on investment opportunities in the equity market with a "high dividend+" strategy [2][3] Group 2: Investment Strategies and Asset Management - The company plans to build a "pyramid-type" asset portfolio to achieve stable returns that exceed market performance, utilizing flexible strategies to manage risks and optimize asset allocation [3] - The company’s affiliate, Invesco Great Wall, has maintained a strong reputation in active equity investment due to its stable governance structure and ability to leverage both domestic policy insights and international resources [3] Group 3: Wealth Management Transformation - The company is actively advancing its wealth management business by establishing a digital framework centered on "digital clients, digital employees, digital products, and digital advisory," focusing on creating a comprehensive advisory product ecosystem [3] - The company aims to build a multi-layered financial product matrix, with a strategic focus on ETF distribution and customized institutional wealth management products, particularly the "Wealth Great Wall · Private 50" product series [3]

Financial Performance - The company repaid all acquisition loans to AVIC Trust amounting to 830 million yuan using self-owned and self-raised funds [1] - For the first half of 2025, the company achieved a total revenue of 179.79 million yuan [2] - The company aims to ensure the completion of its annual operational goals and mitigate delisting risks [3] Employee Information - As of December 31, 2024, the total number of employees is 383, excluding the subsidiary Ruien Pharmaceutical [2] Restructuring Plans - The company is currently in the pre-restructuring phase, with the Chongqing Fifth Intermediate People's Court completing the filing for pre-restructuring [3] - There is significant uncertainty regarding whether the company will formally enter the restructuring process [3] - The company signed restructuring investment agreements with strategic investors in September 2025, which may lead to changes in control [3][4] Debt and Compensation - The company is actively pursuing the collection of performance compensation from individuals, with a total of 135 million yuan already paid by Kou Han and 21.41 million yuan by Lin Jiaxi, leaving outstanding balances of 311.99 million yuan and 22.70 million yuan respectively [5][6] - The company is conducting a debt review as part of the pre-restructuring process, with specific figures to be disclosed in future announcements [5] Future Outlook - The company is focused on improving its core business operations and exploring partnerships to enhance market demand [8] - The introduction of strategic investors is expected to provide financial and operational support to improve the company's performance [9][10] - The company plans to implement a capital increase through the conversion of capital reserves, with a proposed ratio of 10 shares for every 4.8 shares issued [13][14]

| 服务项目（服务期 3 年），教育部教育考试院全国大学四、六级 | | --- | | 考试（CET）项目答题卡扫描及网上评卷技术服务项目（服务期 3 | | 年）、教育部教育考试院中小学教师资格考试（NTCE）项目答题 | | 卡扫描及网上评卷技术服务项目（服务期 3 年）、2025-2028 年 | | 河北省国家教育考试网上评卷技术服务项目（服务期 3 年）等大 | | 型考试项目，标志着在重大考试领域的持续突破与稳定增长。 | | 综合来看，公司凭借在考试测评领域的领先优势、持续的技 | | 术创新及清晰的市场拓展路径，为盈利能力的持续提升奠定了坚 | | 实基础。 | | 2、当前市场高度关注 AI 产业，鸥玛软件作为教育服务公司， | | 如何与 AI 结合并受益？ | | 答：当前，鸥玛软件正致力于深度将人工智能技术与考试测 | | 评服务相融合，以巩固并提升公司核心竞争力。公司以人工智能 | | 创新研究院为技术引擎，持续推进智能识别、智能评卷、智能命 | | 题、智能巡考、智能审查等核心技术的研发与应用。这些技术已 | | 成功应用于国家教育类、资格行业类以及公务员和事业单位招考 | | ...

Group 1: Acquisition and Business Expansion - The acquisition of Ningbo Qixiang enhances the company's capabilities in the consumer electronics market, particularly in electric vehicle charging communication technology [1][3] - The company aims to integrate resources from both entities to expand into emerging consumer battery markets, projecting significant growth potential [3][4] - The company has completed the acquisition of 51% of Ningbo Qixiang, which is now included in the consolidated financial statements [4] Group 2: Financial Performance and Market Strategy - In the first half of 2025, overseas sales revenue reached 186 million, accounting for 34.07% of total revenue, with a year-on-year growth of 19.71% [2][5] - The core business of lithium-ion batteries constitutes 97.48% of total revenue, but the gross margin is only 20.48% [5][6] - The company is focusing on reducing customer concentration and expanding into new sectors such as smart wearables and medical devices [2][6] Group 3: Research and Development Investments - The company invested 150 million in the Wanxiu large-capacity consumer product battery project and 40.8 million in the R&D center by June 30, 2025 [4] - R&D expenditure accounted for 12.53% of total revenue in the first half of 2025, indicating a strong commitment to innovation [4] - The company is actively pursuing advancements in solid-state battery technology and has achieved several patents in this area [4][6] Group 4: Product Development and Market Positioning - The company is enhancing its product offerings in Bluetooth headsets and smart wearable devices to maintain competitiveness [2][5] - Efforts are being made to improve profit margins through product upgrades and efficient production management [4][5] - The company is establishing long-term partnerships with leading brands in various sectors, including smart wearables and drones [2][3]

Group 1: Company Overview - The company primarily engages in the development and utilization of tungsten mining resources, producing ammonium paratungstate (APT), tungsten oxide, tungsten powder, tungsten carbide powder, thermal spray powder, and hard alloy products, establishing a comprehensive tungsten industry chain [2][3] - The upstream business focuses on tungsten ore exploration and selection, with tungsten concentrate as the main product, and by-products including tin and copper concentrates sold externally [2][3] Group 2: Mining Operations - In the first half of 2025, the company produced 1,849.93 tons of tungsten concentrate (WO3 65%), a year-on-year increase of 3.24%; tin concentrate production was 426.12 tons, up 2.71%; and copper concentrate production was 180.61 tons, up 2.02% [5] - The company is advancing resource integration and deep mining construction, enhancing mining and selection efficiency to increase output of tungsten, tin, and copper [6] Group 3: Cost and Procurement - Mining costs are influenced by geological conditions, ore grades, management levels, and labor costs, varying across different mines [7] - The company self-produces all tungsten concentrate for internal use and procures additional tungsten concentrate and APT from external suppliers, ensuring stable supply through rigorous supplier evaluation [8] Group 4: Impact of Raw Material Prices - Rising tungsten concentrate prices positively affect the company, but significant fluctuations in procurement prices can impact production costs and overall business performance [9] Group 5: Sales Performance - In the first half of 2025, tungsten powder sales reached 2,657.83 tons, a 43.68% increase; tungsten carbide powder sales were 2,975.12 tons, up 19.25%; however, hard alloy sales decreased by 7.17% to 573.92 tons, and thermal spray powder sales fell by 1.93% to 222.59 tons [10] Group 6: Subsidiary Performance - In the first half of 2025, the subsidiary Ganzhou Aoketai achieved revenue of 353.53 million yuan, a year-on-year increase of 15.36%, with hard alloy tool sales contributing 189.27 million yuan, up 2.26% [11][12] - Ganzhou Aoketai specializes in cutting tools for difficult-to-machine materials, providing solutions for various industries including automotive, aerospace, and energy [12]

投资者关系活动记录表 编号：2025-002 | | □特定对象调研 □ 分析师会议 | | --- | --- | | □ | 媒体采访 □ 业绩说明会 | | 投资者关系活动 □ | 新闻发布会 □ 路演活动 | | 类别 □ | 现场参观 | | | √其他（重庆辖区 2025 年投资者网上集体接待日暨半年度业绩 | | | 说明会活动） | | 参与单位名称及 | 参加"重庆辖区 2025 年投资者网上集体接待日暨半年度业绩说 | | 人员姓名 | 明会活动"的投资者 | | 时间 2025 | 年 9 月 25 日 (周四) 下午 15:00-17:00 | | 地点 | "全景路演"（http://rs.p5w.net） | | 上市公司接待 | 董事、财务总监：江世学女士 | | 人员姓名 | 副总经理、董事会秘书：周立峰先生 | | | 公司就投资者在本次业绩说明会中提出的问题进行了回复： | | | 1. 油气开发项目预计什么时候有勘探结果？ | | | 您好！公司的油气区块目前正按照制定的勘探方案进行勘探。 | | | 后续勘探工作各个阶段取得进展，公司将及时进行公告，敬请关 | | 注。 ...

Group 1: Company Overview - The company specializes in the research, production, and sales of IoT intelligent products, focusing on communication, positioning, and AI technologies [1] - It aims to become a global expert in IoT intelligent application solutions, adhering to the mission of "empowering everything with wisdom" [1] Group 2: Financial Performance - In 2024, the company achieved a revenue of CNY 1.402 billion, a year-on-year increase of 24.85%, and a net profit of CNY 176 million, up by 0.81% [2] - For the first half of 2025, the revenue reached CNY 805 million, reflecting a 20.17% increase year-on-year, with a net profit of CNY 108 million, an increase of 19.07% [2] Group 3: Product Offerings - The smart vehicle terminal products are categorized into commercial vehicle monitoring terminals and passenger vehicle positioning terminals, featuring functions like intelligent recognition, remote monitoring, and GPS/Beidou positioning [2][3] - The commercial vehicle monitoring terminals are being upgraded to include advanced features such as HD video recording and driver assistance [3] Group 4: Market Strategy - The company is focusing on expanding its market share in Africa, Southeast Asia, and West Asia, while targeting developed regions like Europe and North America for long-term growth [3] - It has entered the qualified supplier list for an overseas automotive brand, enhancing its presence in the overseas vehicle market [3] Group 5: Competitive Advantages - The company’s core competitive advantages include expertise in communication, positioning, and AI algorithms, which address industry pain points [4] - A vertically integrated supply chain comprising modules, terminals, and platforms reduces R&D risks and enhances product competitiveness [4] - Continuous investment in R&D aims to optimize the underlying technology architecture of smart vehicle terminals, improving product stability and adaptability for overseas markets [4]

Group 1: Iodine Applications and Market Overview - Iodine and its derivatives are crucial raw materials in medical, agricultural, industrial, and nutritional fields, widely used in various product formulations as key components or catalysts [2] - The downstream application structure of iodine includes three core areas: X-ray contrast agents, pharmaceutical manufacturing, and LCD panel manufacturing, collectively accounting for approximately 63% of global consumption [2] - Major iodine production is concentrated in three regions: Chile, Japan, and the United States, which together account for 88% of global sales [2] Group 2: Iodine Production and Market Share - Five companies in Chile account for about 60% of global iodine sales, with SQM alone representing approximately 37% [2] - Eight Japanese producers collectively hold around 23% of the market share, while U.S. producers account for nearly 5% [2] - Other countries with minor production include Russia, Turkmenistan, Azerbaijan, Indonesia, and China [3] Group 3: Company Product Offerings - The company’s inorganic iodide products include potassium iodide, potassium iodate, sodium iodide, hydriodic acid, and cuprous iodide, primarily used in pharmaceuticals, pesticides, feed, and optoelectronic materials [3] - The company’s organic iodide product, trimethylsilyl iodide, serves as a protecting group in organic synthesis, mainly applied in pharmaceutical production (e.g., cephalosporins, macrolide antibiotics) [3] - The company has a 4,000 tons/year inorganic iodide production project focusing on potassium iodide, hydriodic acid, ammonium iodide, silver iodide, and lithium iodide [3]

Group 1: Business Overview - The company's main business focuses on urban infrastructure in the Yangtze River Delta region, maintaining stable revenue through consistent order acquisition and prioritizing cash flow stability over high profit margins [2] - The real estate sector is undergoing a phase of inventory reduction, with net profit in the first half of 2024 declining compared to the full year of 2023 due to land value-added tax settlements [2] Group 2: New Energy Business - The new energy sector has turned a net profit of 52 million yuan in the first half of 2025, recovering from losses in previous years, driven by stable component prices and contributions from photovoltaic EPC projects [2] - The expected annual component production is between 2-2.5 GW, with a focus on ODM, while cash flow is projected to balance with ongoing projects [2] Group 3: Investment Strategies - The company adopts a cautious investment approach, typically holding a 35% stake in projects alongside state-owned enterprises, ensuring that self-funded investments do not exceed 10% of total project costs [3] - The Qinghai 80MW photovoltaic power station and the Hangzhou-Shaoxing-Taizhou high-speed rail project are expected to enhance the company's stable profit generation [4] Group 4: Strategic Planning - The company's development strategy integrates "Construction + New Energy + Technology," with a focus on robotics as a new productive force, leveraging its experience in joint R&D and engineering applications [4] - A successful capital increase of 500 million yuan was executed to optimize asset structure and enhance financing pathways, capitalizing on favorable financing policies for real estate companies [4] Group 5: Long-term Investments - Long-term equity investments primarily include PPP projects, such as the Ningbo Zhongxing Bridge, where the company holds a 70% stake, with stable returns expected as the project enters the government buyback phase [5]